iBio Q3 FY2025 net loss widens to $4.9M; pipeline progress with IBIO-600, Activin E

iBio, Inc.

2025-Q3 EPS reported -$1.44 vs consensus -$0.10 ▼ miss (-1276.7%)

Net loss from continuing ops $4.9M ($0.49/share) vs $2.6M ($0.71/share) in Q3 FY2024.
R&D expenses doubled to $1.9M on advancing IBIO-600 and Activin E programs.
Cash $5.2M at March 31; after $6.2M warrant inducement in April, cash ~$10.5M as of May 1.
In-licensed first-in-class Activin E antibody from AstralBio; reported NHP data for IBIO-600 showing dose-dependent muscle growth.
Trading began on Nasdaq under IBIO; on track for IBIO-600 regulatory submission in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.